The full QUEST study results, providing hard evidence about the importance of using Vetmedin, appear in the September/October 2008 issue of the Journal of Veterinary Internal Medicine.
For more information on the QUEST study and on CHF caused by MMVD, please visit http://www.questtrial.com
Boehringer Ingelheim
Boehringer Ingelheim Animal Health and Boehringer Ingelheim Vetmedica belong to the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of almost 11 billion euro while spending one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
The animal health business is conducted in more than 20 countries including USA, Canada, France, Germany, UK, Italy, Spain, Mexico, the Nordic countries Japan and China. Since 1955, Boehringer Ingelheim Animal Health is contributing to an adequate supply of safe, nutritious food and is promoting the emotional and physical benefits arising from the human-animal bond.
For more information, please visit http://www.boehringer-ingelheim.com
---------------------------------
References
(1) Häggström J, Boswood A, O'Grady M et al. Effect of Pimobendan or
Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart
Failure Caused by Naturally Occurring Myxomatous Mitral V
'/>"/>
| SOURCE Boehringer Ingelheim Animal Health Copyright©2008 PR Newswire. All rights reserved |